Stephen D. Wiviott

Antiplatelet Therapy in Ischemic Heart Disease

• Gebundenes Buch

Produktbeschreibung

THE AHA CLINICAL SERIES

ELLIOTT ANTMAN, MD, SERIES EDITOR

The strategic driving force behind the American HeartAssociation's mission of healthier lives free ofcardiovascular disease and stroke is to change practice byproviding information and solutions to healthcare professionals.

---

_ Draws from expertise of leaders in antiplatelet therapy
_ Easy-to-use layout enables rapid browsing
_ Edited by a member of the prestigious TIMI study group with long-standing experience in the field

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• American Heart Association Clinical Series
• Verlag: Wiley & Sons
• 1. Auflage
• Seitenzahl: 312
• Erscheinungstermin: 1. Dezember 2008
• Englisch
• Abmessung: 231mm x 161mm x 23mm
• Gewicht: 584g
• ISBN-13: 9781405176262
• ISBN-10: 1405176261
• Artikelnr.: 23506948

Autorenporträt

Stephen D. Wiviott, MD., Investigator TIMI Study Group, Associate Physician, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Inhaltsangabe

Part I Concepts in Platelet Physiology, Function and Measurement.
1 Platelet physiology and the role of the platelet in ischemic heart
disease.
Robert F. Storey .
2 Laboratory assessment of platelet function and the effects of
antiplatelet agents.
Alan D. Michelson, A.L. Frelinger .
Part II Pharmacology of Oral Antiplatelet Agents.
3 Cyclooxygenase inhibitors.
Nina Chetty Raju, John W. Eikelboom .
4 Aspirin response variability and resistance.
Wai-Hong Chen, Daniel I. Simon .
5 P2Y12 inhibitors: Thienopyridines and direct oral inhibitors.
Jean-Philippe Collet, Boris Aleil, Christian Gachet, Gilles Montalescot .
6 Thienopyridine response variability and resistance.
Udaya S. Tantry, Thomas A. Suarez, Paul A. Gurbel .
Part III Pharmacology of Intravenous Antiplatelet Agents.
7 Pharmacology of intravenous glycoprotein IIb/IIIa antagonists.
James C. Blankenship, Peter B. Berger .
8 Intravenous P2Y12 inhibitors.
Steven P. Dunn, Steven R. Steinhubl .
9 Antiplatelet effects of thrombin inhibitors and fibrinolytic agents.
Nicolai Mejevoi, Anjum Tanwir, Marc Cohen .
Part IV Clinical Use of Antiplatelet Agents in Cardiovascular Disease.
10 Antiplatelet therapy in acute coronary syndrome with ST elevation.
Christian W. Hamm .
11 Antiplatelet therapy in ST-elevation myocardial infarction.
Michelle O'Donoghue, Marc S. Sabatine .
12 Antiplatelet therapy in chronic artery disease.
Kamran I. Muhammed, Deepak L. Bhatt .
13 Antiplatelet therapy in peripheral arterial disease.
Esther S. Kim, Heather L. Gornik .
14 Clinical use of antiplatelet agents in cardiovascular disease:
cerebrovascular diseases.
Larry B. Goldstein .
Part V Special Circumstances.
15 Antiplatelet therapy and coronary bypass surgery: risks and benefits.
A. Burdess, N.L. Cruden, K.A. Fox .
16 Management of antiplatelet therapy for non-cardiac surgery.
Nisheeth Goel, John F. Canales, James J. Ferguson .
17 Antiplatelet therapy and coronary stents.
Alanna Coolong, Laura Mauri